The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in humans. If you are considering using a mouse model of pulmonary fibrosis for drug evaluation studies, then using a suitable study design allows you to best evaluate the efficacy of your compound.
As mentioned in a previous news, if you want to use mice with low fibrotic repair capacity or if you want to conduct a study in which long-term administration is required, e.g. for cell therapy, then it is important to use a study design that is appropriate for those purposes.
The content of previously sent emails can be found here.
As a non-clinical stage consulting CRO, we specialize in understanding our clients’ objectives and proposing study designs accordingly. As a result of this, we have conducted more than 150 drug efficacy evaluation studies using IPF mouse models, and those results have been showcased in numerous papers and conferences.
The following figure shows study designs for both Standard and Chronic BLM models. For compounds that would require a longer time to show their efficacy, such as cellular and nucleic acid therapies, the Chronic BLM model may be more appropriate.
In addition, some data analysis from the above study designs are presented below.
When considering therapeutic studies for fibrosis, the Chronic BLM model allows for long-term administration, from 4 weeks to a maximum of 8 weeks after disease induction. This inflammation induction period is longer than standard models and can be used for the evaluation of compounds with anti-inflammatory properties.
Do you have a design in mind to evaluate your compound?
If you share that study design with us, we can propose an optimal study plan for the evaluation of your compound, as well as a quote for said study.
If you are interested in our services, please feel free to contact us.